Breaking Finance News

finnCap disclosed Cambridge Cognition Holdings (LON:COG), supporting its stock price target at 100.00GBX earlier today

Only yesterday Cambridge Cognition Holdings (LON:COG) traded 0.00% even at 43.50GBX. Cambridge Cognition Holdings’s 50-day average is 53.18GBX and its two hundred day average is 45.28GBX. With the last close down 47.98% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the same time period. Trading volume was was down over the average, with 11,958 shares of COG changing hands under the typical 32,794 shares..

finnCap held the target price of Cambridge Cognition Holdings (LON:COG) at 100GBX, indicating a possible upside of 1.30%,

Previously on Wednesday July 20 2016, FinnCap reported about Cambridge Cognition Holdings(LON:COG) upped the target price from 0.00GBX to 100.00GBX. At the time, this indicated a possible upside of 1.99%.

See Graphic Below:

Cambridge Cognition Holdings (LON:COG)

In addition to finnCap reporting it’s price target, a total of 1 analysts has released a research note on the stock. The consensus target stock price is 100.00GBX with 0 rating the company a strong buy, 0 rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firms rating the stock as sell.

Cambridge Cognition Holdings has a 52 week low of 30.00GBX and a 52 week high of 105.00GBX . The company’s market capitalization is currently 0.0 GBX.

General Company Details For Cambridge Cognition Holdings (LON:COG)

Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company’s segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company’s product, CANTAB Mobile is a Class II medical device, and used to identify patients exhibiting the early signs of Alzheimer’s disease. It also offers Cantab Insight for dementia assessment in secondary care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *